News Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
7.6 ^USD	+3.12%		+10.79%	-37.91%

01/04	Sector Update: Health Care Stocks Slide Late Afternoon	MT
01/04	Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024	25/04	BU
Sector Update: Health Care Stocks Slide Late Afternoon	02/04	MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	01/04	MT
Transcript : Pulse Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024	29/03
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results	29/03	BU
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03	CI
Pulse Biosciences Announces Plans to Initiate a Rights Offering	29/03	BU
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024	15/03	BU
Sector Update: Health Care Stocks Ease Late Afternoon	09/03	MT
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	09/03	MT
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System	08/03	BU
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	08/03	CI
PULSE BIOSCIENCES ANNOUNCES POSITIVE 60-DAY FOLLOW-UP EVALUATIONS FOR INITIAL PATIENTS TREATED IN THE CELLFX NSPFA 360-degree CARDIAC CATHETER FIRST-IN-HUMAN FEASIBILITY STUDY	15/02	AQ
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	14/02	CI
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study	14/02	BU
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium	31/01	BU
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02/01	MT
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	02/01	MT
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	02/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Summary

Filters